Research graph
References from Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
The role of m6A epigenetic modification in the treatment of colorectal cancer immune checkpoint inhibitors
10.3389/fimmu.2021.802049 · 2021 · External reference
Radiolabelled polymeric materials for imaging and treatment of cancer: quo vadis?
10.1002/adhm.201601115 · 2017 · External reference
10.1158/2159-8290.cd-18-0367
10.1158/2159-8290.cd-18-0367 · External reference
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
10.1038/ncomms14754 · 2017 · External reference
10.1126/science.aaa6204
10.1126/science.aaa6204 · External reference
10.1038/nrendo.2016.205
10.1038/nrendo.2016.205 · External reference
10.1146/annurev-pathol-042020-042741
10.1146/annurev-pathol-042020-042741 · External reference
10.3389/fcell.2020.00672
10.3389/fcell.2020.00672 · External reference
10.1038/bjc.2017.434
10.1038/bjc.2017.434 · External reference
EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming
10.1158/0008-5472.can-17-0899 · 2017 · External reference
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways
10.1186/s13073-016-0361-5 · 2016 · External reference
10.1021/mp3004622
10.1021/mp3004622 · External reference
m6A-Atlas: a comprehensive knowledgebase for unraveling the N6-methyladenosine (m6A) epitranscriptome
10.1093/nar/gkaa692 · 2021 · External reference
10.1038/nrm.2016.132
10.1038/nrm.2016.132 · External reference
10.1016/j.cell.2017.05.045
10.1016/j.cell.2017.05.045 · External reference
N6-methyladenosine marks primary microRNAs for processing
10.1038/nature14281 · 2015 · External reference
10.1038/nature12730
10.1038/nature12730 · External reference
The role of m(6)A RNA methylation in human cancer
10.1186/s12943-019-1033-z · 2019 · External reference
10.1038/s41590-020-0650-4
10.1038/s41590-020-0650-4 · External reference
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer
10.1186/s12943-021-01447-y · 2022 · External reference
10.1172/jci31405
10.1172/jci31405 · External reference
10.1038/nrclinonc.2016.144
10.1038/nrclinonc.2016.144 · External reference
10.1111/j.1365-2567.2007.02587.x
10.1111/j.1365-2567.2007.02587.x · External reference
10.1172/jci80011
10.1172/jci80011 · External reference
10.1038/s42003-020-0845-0
10.1038/s42003-020-0845-0 · External reference
Delicate role of PD-L1/PD-1 axis in blood vessel inflammatory diseases: current insight and future significance
10.3390/ijms21218159 · 2020 · External reference
10.1016/j.it.2006.02.001
10.1016/j.it.2006.02.001 · External reference
10.1186/1756-8722-6-74
10.1186/1756-8722-6-74 · External reference
Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics
10.1208/s12248-021-00574-0 · 2021 · External reference
10.1038/s12276-018-0191-1
10.1038/s12276-018-0191-1 · External reference
FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond
10.1634/theoncologist.2017-0078 · 2017 · External reference
Pembrolizumab use in bladder cancer: a tale of two trials
10.1038/s41585-021-00499-5 · 2021 · External reference
Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting
2019 · External reference
Pembrolizumab in classical Hodgkin's lymphoma
10.1111/ejh.12770 · 2016 · External reference
Pembrolizumab for the treatment of esophageal cancer
10.1080/14712598.2020.1792881 · 2020 · External reference
10.1093/intimm/dxu095
10.1093/intimm/dxu095 · External reference
10.1016/s0140-6736(16)32455-2
10.1016/s0140-6736(16)32455-2 · External reference
10.1056/nejmoa1716948
10.1056/nejmoa1716948 · External reference
10.1080/14737140.2018.1445528
10.1080/14737140.2018.1445528 · External reference
Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
10.1056/nejmoa2002788 · 2020 · External reference
10.1016/s1470-2045(18)30107-4
10.1016/s1470-2045(18)30107-4 · External reference
Erratum to: durvalumab: first global approval
10.1007/s40265-017-0826-x · 2017 · External reference
10.1016/s0140-6736(19)32222-6
10.1016/s0140-6736(19)32222-6 · External reference
CD28 co-stimulation in T-cell homeostasis: a recent perspective
2015 · External reference
10.1016/1074-7613(94)90071-x
10.1016/1074-7613(94)90071-x · External reference
10.1126/science.282.5397.2263
10.1126/science.282.5397.2263 · External reference
10.1038/nri1248
10.1038/nri1248 · External reference
10.1016/s0952-7915(97)80087-8
10.1016/s0952-7915(97)80087-8 · External reference
10.1084/jem.182.2.459
10.1084/jem.182.2.459 · External reference
10.1084/jem.20082492
10.1084/jem.20082492 · External reference
10.1016/j.ijcha.2019.100420
10.1016/j.ijcha.2019.100420 · External reference
Chimeric antigen receptor T-cell therapy for colorectal cancer
2020 · External reference
Ipilimumab and nivolumab as first-line treatment of patients with renal cell carcinoma: the evidence to date
10.2147/cmar.s202017 · 2020 · External reference
10.1016/s1470-2045(16)30624-6
10.1016/s1470-2045(16)30624-6 · External reference
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
10.1016/s0140-6736(20)32714-8 · 2021 · External reference
10.1073/pnas.1120606109
10.1073/pnas.1120606109 · External reference
10.1126/science.1260419
10.1126/science.1260419 · External reference
10.1038/ni.1674
10.1038/ni.1674 · External reference
10.4049/jimmunol.1003081
10.4049/jimmunol.1003081 · External reference
10.1158/1078-0432.ccr-17-2337
10.1158/1078-0432.ccr-17-2337 · External reference
10.3390/biomedicines9091277
10.3390/biomedicines9091277 · External reference
10.1084/jem.176.2.327
10.1084/jem.176.2.327 · External reference
LAG-3 in Cancer Immunotherapy
2011 · External reference
10.1038/ni.2035
10.1038/ni.2035 · External reference
10.1007/s40265-022-01723-1
10.1007/s40265-022-01723-1 · External reference
Corrigendum: an IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction
10.1038/ncomms8657 · 2015 · External reference
Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma
10.1007/s00345-015-1656-7 · 2016 · External reference
Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors
10.1158/0008-5472.can-11-0096 · 2011 · External reference
Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating t cells in hepatocellular carcinomas
10.1053/j.gastro.2017.06.017 · 2017 · External reference
10.1093/annonc/mdv383
10.1093/annonc/mdv383 · External reference
10.1200/jco.2018.78.2276
10.1200/jco.2018.78.2276 · External reference
Characterization of diabetogenic CD8+ T cells: immune therapy with metabolic blockade
10.1074/jbc.m115.713362 · 2016 · External reference
10.1056/nejmoa1500596
10.1056/nejmoa1500596 · External reference
10.1001/jamanetworkopen.2019.2535
10.1001/jamanetworkopen.2019.2535 · External reference
10.1038/nri.2016.107
10.1038/nri.2016.107 · External reference
10.1016/j.omtn.2019.11.022
10.1016/j.omtn.2019.11.022 · External reference
10.1038/nature18298
10.1038/nature18298 · External reference
Interactions, localization, and phosphorylation of the m(6)A generating METTL3-METTL14-WTAP complex
10.1261/rna.064063.117 · 2018 · External reference
10.1038/nchembio.1432
10.1038/nchembio.1432 · External reference
10.1038/cr.2014.3
10.1038/cr.2014.3 · External reference
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential
10.1186/s13045-021-01129-8 · 2021 · External reference
VIRMA mediates preferential m(6)A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation
10.1038/s41421-018-0019-0 · 2018 · External reference
10.1038/s41388-019-0861-z
10.1038/s41388-019-0861-z · External reference
Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m(6)A machinery component Wtap/Fl(2)d
10.1101/gad.309146.117 · 2018 · External reference
10.1016/j.cell.2012.05.003
10.1016/j.cell.2012.05.003 · External reference
10.1038/nchembio.687
10.1038/nchembio.687 · External reference
10.1016/j.molcel.2012.10.015
10.1016/j.molcel.2012.10.015 · External reference
10.1038/cr.2014.151
10.1038/cr.2014.151 · External reference
10.1016/j.molcel.2016.01.012
10.1016/j.molcel.2016.01.012 · External reference
Dynamic m(6)A mRNA methylation directs translational control of heat shock response
10.1038/nature15377 · 2015 · External reference
10.1038/cr.2017.15
10.1038/cr.2017.15 · External reference
The role of m(6)A modification in physiology and disease
10.1038/s41419-020-03143-z · 2020 · External reference
10.20892/j.issn.2095-3941.2019.0347
10.20892/j.issn.2095-3941.2019.0347 · External reference
10.1038/s41556-018-0045-z
10.1038/s41556-018-0045-z · External reference
10.1172/jci126199
10.1172/jci126199 · External reference
10.1038/nature23450
10.1038/nature23450 · External reference
m(6)A mRNA methylation sustains Treg suppressive functions
10.1038/cr.2018.7 · 2018 · External reference
METTL3-dependent m(6)A modification programs T follicular helper cell differentiation
10.1038/s41467-021-21594-6 · 2021 · External reference
10.1073/pnas.1918986117
10.1073/pnas.1918986117 · External reference
10.1038/s41577-019-0210-z
10.1038/s41577-019-0210-z · External reference
Mettl3-mediated mRNA m(6)A methylation promotes dendritic cell activation
10.1038/s41467-019-09903-6 · 2019 · External reference
10.1038/s41586-019-0916-x
10.1038/s41586-019-0916-x · External reference
10.1038/nrclinonc.2016.217
10.1038/nrclinonc.2016.217 · External reference
10.1016/j.ccell.2021.04.016
10.1016/j.ccell.2021.04.016 · External reference
10.1038/s41467-021-21514-8
10.1038/s41467-021-21514-8 · External reference
10.1038/s41467-021-25803-0
10.1038/s41467-021-25803-0 · External reference
10.1101/2021.04.26.441557
10.1101/2021.04.26.441557 · External reference
10.1158/2159-8290.cd-20-1848
10.1158/2159-8290.cd-20-1848 · External reference
N6-methyladenine-related genes affect biological behavior and the prognosis of glioma
10.1002/cam4.3574 · 2021 · External reference
Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas
10.21037/atm-21-3139 · 2021 · External reference
N6-methyladenosine regulator-mediated immue patterns and tumor microenvironment infiltration characterization in glioblastoma
10.3389/fimmu.2022.819080 · 2022 · External reference
The role of m6A regulator-mediated methylation modification and tumor microenvironment infiltration in glioblastoma multiforme
10.3389/fcell.2022.842835 · 2022 · External reference
The N6-methyladenosine-modified pseudogene HSPA7 correlates with the tumor microenvironment and predicts the response to immune checkpoint therapy in glioblastoma
10.3389/fimmu.2021.653711 · 2021 · External reference
RNA N6-methyladenosine regulator-mediated methylation modifications pattern and immune infiltration features in glioblastoma
10.3389/fonc.2021.632934 · 2021 · External reference
N(6)-methyladenosine-modified circIGF2BP3 inhibits CD8(+) T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer
10.1186/s12943-021-01398-4 · 2021 · External reference
10.1016/j.omto.2020.03.021
10.1016/j.omto.2020.03.021 · External reference
m(6)A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer
10.1186/s12916-021-02148-5 · 2021 · External reference
m(6)A regulator-mediated methylation modification patterns and characterisation of tumour microenvironment infiltration in non-small cell lung cancer
10.2147/jir.s356841 · 2022 · External reference
m(6)A modification patterns and tumor immune landscape in clear cell renal carcinoma
10.1136/jitc-2020-001646 · 2021 · External reference
m(6)A regulator-mediated methylation modification model predicts prognosis, tumor microenvironment characterizations and response to immunotherapies of clear cell renal cell carcinoma
10.3389/fonc.2021.709579 · 2021 · External reference
Interaction between N(6)-methyladenosine (m(6)A) modification and noncoding RNAs in cancer
10.1186/s12943-020-01207-4 · 2020 · External reference
10.1016/j.ccell.2020.02.004
10.1016/j.ccell.2020.02.004 · External reference
KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3
10.1186/s12943-019-1106-z · 2019 · External reference
Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma
10.1002/iid3.513 · 2021 · External reference
Radiogenomics map reveals the landscape of m6A methylation modification pattern in bladder cancer
10.3389/fimmu.2021.722642 · 2021 · External reference
An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer
10.1186/s12885-021-08981-4 · 2021 · External reference
m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer
10.1186/s12943-020-01170-0 · 2020 · External reference
N(6)-methyladenosine (m(6)A) RNA methylation signature as a predictor of stomach adenocarcinoma outcomes and its association with immune checkpoint molecules
2020 · External reference
Identification of a robust signature for clinical outcomes and immunotherapy response in gastric cancer: based on N6-methyladenosine related long noncoding RNAs
10.1186/s12935-021-02146-w · 2021 · External reference
Comprehensive analysis of PD-L1 expression, immune infiltrates, and m6A RNA methylation regulators in esophageal squamous
2021 · External reference
m(6)A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer
10.7150/thno.52717 · 2021 · External reference
Integrated analysis of the immune infiltrates and PD-L1 expression of N6-methyladenosine-related long non-coding RNAs in colorectal cancer
10.2147/ijgm.s327765 · 2021 · External reference
10.1016/j.bbrc.2020.06.153
10.1016/j.bbrc.2020.06.153 · External reference
m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy
10.15252/embj.2020104514 · 2020 · External reference
Identification of an m6A-related signature as biomarker for hepatocellular carcinoma prognosis and correlates with sorafenib and anti-PD-1 immunotherapy treatment response
10.1155/2021/5576683 · 2021 · External reference
Analysis of m6A-related lncRNAs for prognosis value and response to immune checkpoint inhibitors therapy in hepatocellular carcinoma
10.2147/cmar.s322179 · 2021 · External reference
CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m(6)A modification in hepatocellular carcinoma
10.1016/j.omto.2022.02.021 · 2022 · External reference
10.18632/aging.203939
10.18632/aging.203939 · External reference
10.1016/j.ebiom.2021.103271
10.1016/j.ebiom.2021.103271 · External reference
The expression of m(6)A regulators correlated with the immune microenvironment plays an important role in the prognosis of pancreatic ductal adenocarcinoma
10.21037/gs-21-859 · 2022 · External reference
10.1038/s41417-020-00208-1
10.1038/s41417-020-00208-1 · External reference
Classification and immune invasion analysis of breast cancer based on m6A genes
10.21037/atm-21-3404 · 2021 · External reference
Significance of N6-methyladenosine RNA methylation regulators in immune infiltrates of ovarian cancer
10.3389/fgene.2021.671179 · 2021 · External reference
Characterization of the m6A-associated tumor immune microenvironment in prostate cancer to aid immunotherapy
10.3389/fimmu.2021.735170 · 2021 · External reference
m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in acute myeloid leukemia
10.3389/fimmu.2021.789914 · 2021 · External reference
10.1016/j.ccell.2020.04.017
10.1016/j.ccell.2020.04.017 · External reference
10.1002/smll.202106558
10.1002/smll.202106558 · External reference
m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
10.1038/s41467-019-10669-0 · 2019 · External reference
10.1021/acs.biomac.1c01571
10.1021/acs.biomac.1c01571 · External reference
METTL3 intensifies the progress of oral squamous cell carcinoma via modulating the m6A amount of PRMT5 and PD-L1
2021 · External reference
Immune infiltrates of m(6)A RNA methylation-related lncRNAs and identification of PD-L1 in patients with primary head and neck squamous cell carcinoma
10.3389/fcell.2021.672248 · 2021 · External reference
Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma
10.1002/jcla.24113 · 2022 · External reference
10.1016/j.omtn.2020.06.001
10.1016/j.omtn.2020.06.001 · External reference
10.1371/journal.pone.0159072
10.1371/journal.pone.0159072 · External reference
Fluorescein derivatives as bifunctional molecules for the simultaneous inhibiting and labeling of FTO protein
10.1021/jacs.5b06690 · 2015 · External reference
10.1093/nar/gku1276
10.1093/nar/gku1276 · External reference
10.1021/ja3064149
10.1021/ja3064149 · External reference
10.1021/acs.biochem.6b00023
10.1021/acs.biochem.6b00023 · External reference
10.1021/acs.jmedchem.5b00702
10.1021/acs.jmedchem.5b00702 · External reference
10.1016/j.cell.2017.11.031
10.1016/j.cell.2017.11.031 · External reference
10.1016/j.cmet.2021.04.001
10.1016/j.cmet.2021.04.001 · External reference
Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m(6)A signaling
10.7150/thno.55574 · 2021 · External reference
Identification of Clausine E as an inhibitor of fat mass and obesity-associated protein (FTO) demethylase activity
10.1002/jmr.2800 · 2019 · External reference
10.1016/j.celrep.2017.02.059
10.1016/j.celrep.2017.02.059 · External reference
10.1016/j.ccell.2019.03.006
10.1016/j.ccell.2019.03.006 · External reference
Rational design of novel anticancer small-molecule RNA m6A demethylase ALKBH5 inhibitors
10.1021/acsomega.1c01289 · 2021 · External reference
10.1002/med.21565
10.1002/med.21565 · External reference
Discovery of two novel ALKBH5 selective inhibitors that exhibit uncompetitive or competitive type and suppress the growth activity of glioblastoma multiforme
10.1111/cbdd.14051 · 2022 · External reference
10.1038/s41586-021-03536-w
10.1038/s41586-021-03536-w · External reference
Mining for METTL3 inhibitors to suppress cancer
10.1038/s41594-021-00606-5 · 2021 · External reference
Effects of quercetin on the efficacy of various chemotherapeutic drugs in cervical
2021 · External reference
10.1039/c8fo02004c
10.1039/c8fo02004c · External reference
10.1016/j.stem.2017.11.016
10.1016/j.stem.2017.11.016 · External reference
A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation
10.1016/j.tranon.2017.07.008 · 2017 · External reference
The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer
10.1093/nar/gkaa653 · 2020 · External reference
10.1038/sj.onc.1209080
10.1038/sj.onc.1209080 · External reference
